Overview of bladder cancer trials in the Radiation Therapy Oncology Group (Q35098002)

6 August 2017

1 reference

title

Overview of bladder cancer trials in the Radiation Therapy Oncology Group (English)

1 reference

Adaptive radiation therapy

6 August 2017

0 references

1 reference

William U Shipley

1

1 reference

6 August 2017

Donald S Kaufman

2

1 reference

6 August 2017

William J Tester

3

1 reference

6 August 2017

Miljenko V Pilepich

4

1 reference

6 August 2017

Howard M Sandler

5

1 reference

6 August 2017

Radiation Therapy Oncology Group

6

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

6 August 2017

5

1 reference

inferred from page(s)

published in

Cancer

1 reference

6 August 2017

97

1 reference

6 August 2017

8 Suppl

1 reference

6 August 2017

2115-2119

1 reference

Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12

6 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11282

Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11282

7 January 2021

Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11282

7 January 2021

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11282

7 January 2021

The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11282

7 January 2021

Selective bladder preservation by combination treatment of invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11282

7 January 2021

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11282

7 January 2021

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11282

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11282

7 January 2021

Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11282

7 January 2021

Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11282

7 January 2021

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11282

7 January 2021

Identifiers

DOI

10.1002/CNCR.11282

1 reference

release_fyrnvj2sxrhurbeegvkn6pesvu

6 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fyrnvj2sxrhurbeegvkn6pesvu

24 November 2022

mapped directly with Wikidata item

1 reference